Curtis A. Engelhart

Curtis A. Engelhart

Auto-generated profile, based on publicly available information

Curtis A. Engelhart

Department of Microbiology and Immunology, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2022 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
SLShuqi Li
Shuqi Li
NPNicholas C. Poulton
Nicholas C. Poulton
JCJesseon S. Chang
Jesseon S. Chang
ZAZachary A. Azadian
Zachary A. Azadian
MDMichael A. DeJesus
Michael A. DeJesus
JRJeremy M. Rock
Jeremy M. Rock
Mycobacterium tuberculosis (Mtb) infection is notoriously difficult to treat. Treatment efficacy is limited by Mtb’s intrinsic drug resistance, as well as its ability to evolve acquired resistance to all antituberculars in clinical use. A deeper understanding of the bacterial pathways that influence drug efficacy could facilitate the development of more effective therapies, identify new mechanisms of acquired resistance, and reveal overlooked therapeutic opportunities. Here we developed a CRISPR interference chemical-genetics platform to titrate the expression of Mtb genes and quantify bacterial fitness in the presence of different drugs. We discovered diverse mechanisms of intrinsic drug resistance, unveiling hundreds of potential targets for synergistic drug combinations. Combining chemical genetics with comparative genomics of Mtb clinical isolates, we further identified several previously unknown mechanisms of acquired drug resistance, one of which is associated with a multidrug-resistant tuberculosis outbreak in South America. Lastly, we found that the intrinsic resistance factor whiB7 was inactivated in an entire Mtb sublineage endemic to Southeast Asia, presenting an opportunity to potentially repurpose the macrolide antibiotic clarithromycin to treat tuberculosis. This chemical-genetic map provides a rich resource to understand drug efficacy in Mtb and guide future tuberculosis drug development and treatment.

31 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TBTiago Beites
Tiago Beites
KOKathryn O’brien
Kathryn O’brien
DTDivya Tiwari
Divya Tiwari
CECurtis A. Engelhart
Curtis A. Engelhart
SWShaun Walters
Shaun Walters
DSDirk Schnappinger
Dirk Schnappinger
The viability of Mycobacterium tuberculosis (Mtb) depends on energy generated by its respiratory chain. Cytochrome bc1-aa3 oxidase and type-2 NADH dehydrogenase (NDH-2) are respiratory chain components predicted to be essential, and are currently targeted for drug development. Here we demonstrate that an Mtb cytochrome bc1-aa3 oxidase deletion mutant is viable and only partially attenuated in mice. Moreover, treatment of Mtb-infected marmosets with a cytochrome bc1-aa3 oxidase inhibitor controls disease progression and reduces lesion-associated inflammation, but most lesions become cavitary. Deletion of both NDH-2 encoding genes (Δndh-2 mutant) reveals that the essentiality of NDH-2 as shown in standard growth media is due to the presence of fatty acids. The Δndh-2 mutant is only mildly attenuated in mice and not differently susceptible to clofazimine, a drug in clinical use proposed to engage NDH-2. These results demonstrate the intrinsic plasticity of Mtb’s respiratory chain, and highlight the challenges associated with targeting the pathogen’s respiratory enzymes for tuberculosis drug development.

1 February 2019 in Science
Verified
Journal Article
Open access
PDF file
EBElaine Ballinger
Elaine Ballinger
JMJohn Mosior
John Mosior
THTravis Hartman
Travis Hartman
KBKristin Burns-Huang
Kristin Burns-Huang
BGBen Gold
Ben Gold
CNCarl Nathan
Carl Nathan
A wrench in the gears of life: Tuberculosis is a global health crisis that threatens to become worse as resistance to existing drugs emerges. Identifying ideal targets for drug development requires knowledge of weak points in biochemical pathways that are specific for the pathogen but are absent in hosts. Ballinger et al. identified a small molecule that inhibits the enzyme phosphopantetheinyl transferase (PptT), which is crucial for biosynthesis of mycobacterial structural and virulence lipids (see the Perspective by Mizrahi and Warner). Treatment resulted in selective killing of the bacteria in vitro and in a mouse model. The target pathways were made sensitive to PptT inhibition by a second enzyme, phosphopantetheine hydrolase, whose activity opposes that of the transferase. Science , this issue p. eaau8959 ; see also p. 457

11 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGSimon R. Green
Simon R. Green
SDSusan H. Davis
Susan H. Davis
SDSebastian Damerow
Sebastian Damerow
CECurtis A. Engelhart
Curtis A. Engelhart
MMMichael Mathieson
Michael Mathieson
LCLaura A. T. Cleghorn
Laura A. T. Cleghorn
Tuberculosis is a major global cause of both mortality and financial burden mainly in low and middle-income countries. Given the significant and ongoing rise of drug-resistant strains of Mycobacterium tuberculosis within the clinical setting, there is an urgent need for the development of new, safe and effective treatments. Here the development of a drug-like series based on a fused dihydropyrrolidino-pyrimidine scaffold is described. The series has been developed against M. tuberculosis lysyl-tRNA synthetase (LysRS) and cellular studies support this mechanism of action. DDD02049209, the lead compound, is efficacious in mouse models of acute and chronic tuberculosis and has suitable physicochemical, pharmacokinetic properties and an in vitro safety profile that supports further development. Importantly, preliminary analysis using clinical resistant strains shows no pre-existing clinical resistance towards this scaffold.

30 July 2025 in Nature
Verified
Journal Article
Closed access
PDF file
IKInna V. Krieger
Inna V. Krieger
PSParidhi Sukheja
Paridhi Sukheja
BYBaiyuan Yang
Baiyuan Yang
STSu Tang
Su Tang
DSDaniel Selle
Daniel Selle
CMCase W. McNamara
Case W. McNamara

25 April 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
DTDivya Tiwari
Divya Tiwari
SPSae Woong Park
Sae Woong Park
MEMaram Essawy
Maram Essawy
SDSurendra Dawadi
Surendra Dawadi
AMAlan Mason
Alan Mason
DSDirk Schnappinger
Dirk Schnappinger
Inhibitors of biotin protein ligase and protein biotinylation in Mycobacterium tuberculosis act synergistically with the drug rifampicin, potentially shortening tuberculosis treatment.